Clinical Trial Update: Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the addition of on-demand isatuximab to Iberdomide, bortezomib, and dexamethasone in newly diagnosed, non-transplant-eligible multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• SARCLISA (isatuximab)
• iberdomide (iberdomide)

Snippet

Sponsor: Canadian Myeloma Research Group | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING